|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400091707 |
|
最近更新日期: Date of Last Refreshed on: |
2024-11-01 14:46:24 |
|
注册时间: Date of Registration: |
2024-11-01 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
磁共振新序列在肾脏肿瘤的应用 |
|
Public title: |
Application of new magnetic resonance sequences in renal tumors |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
磁共振新序列在肾脏肿瘤的应用 |
|
Scientific title: |
Application of new magnetic resonance sequences in renal tumors |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王嘉晖 |
研究负责人: |
马恒 |
|
Applicant: |
JiaHui Wang |
Study leader: |
Heng Ma |
|
申请注册联系人电话: Applicant telephone: |
+86 198 6112 1070 |
研究负责人电话: Study leader's telephone: |
+86 159 0891 5896 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1094383578@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
mhyhd@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
烟台市芝罘区毓璜顶东路20号 |
研究负责人通讯地址: |
烟台市芝罘区毓璜顶东路20号 |
|
Applicant address: |
No. 20, Yuhuangding East Road, Zhifu District, Yantai City |
Study leader's address: |
No. 20, Yuhuangding East Road, Zhifu District, Yantai City |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
烟台毓璜顶医院 |
||
|
Applicant's institution: |
Yantai Yuhuangding Hospital |
||
|
研究负责人所在单位: |
烟台毓璜顶医院 |
||
|
Affiliation of the Leader: |
Yantai Yuhuangding Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
烟毓医伦理审[2024-709]号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国山东省烟台市烟台毓璜顶医院伦理委员会 |
||
|
Name of the ethic committee: |
Institutional Ethics Committee of Yantai Yuhuangding Hospital, Yantai, Shandong Province, China |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-10-28 00:00:00 |
||
|
伦理委员会联系人: |
李老师 |
||
|
Contact Name of the ethic committee: |
Mr. Li |
||
|
伦理委员会联系地址: |
烟台市芝罘区毓璜顶东路20号 |
||
|
Contact Address of the ethic committee: |
No. 20, Yuhuangding East Road, Zhifu District, Yantai City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 535 622 9756 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
烟台毓璜顶医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Yantai Yuhuangding Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
烟台市芝罘区毓璜顶东路20号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 20, Yuhuangding East Road, Zhifu District, Yantai City |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded |
||||||||||||||||||||||
|
Target disease: |
Kidney tumor |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
通过利用磁共振新序列对肾肿瘤患者进行无创扫描获得新参数,从而对肾肿瘤进行更好评估,帮助临床对患者进行治疗及预后管理 |
||||||||||||||||||||||
|
Objectives of Study: |
By using the new magnetic resonance sequence to obtain new parameters for non-invasive scanning of kidney tumor patients, so as to better evaluate kidney tumor and help clinical treatment and prognosis management of patients |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
通过CT明确为肾肿瘤的患者 |
||||||||||||||||||||||
|
Inclusion criteria |
Patients with renal tumors confirmed by CT |
||||||||||||||||||||||
|
排除标准: |
1.存在严重的急性并发症或病情不稳定的患者。 2.在过去五年内患有其他原发性恶性肿瘤。 3.由于认知障碍、精神疾病等原因无法配合完成MRI检查的患者。 4.体内有金属植入物或其他MRI禁忌症的患者。 5.肿瘤已手术切除 6.未签署知情同意书的患者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with severe acute complications or unstable condition. 2. Other primary malignancies within the past five years. 3. Patients who are unable to cooperate with the completion of MRI examination due to cognitive impairment, mental illness, etc. 4. Patients with metal implants or other contraindications to MRI in the body. 5. The tumor has been surgically removed 6.Patients who have not signed the informed consent form |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-10-21 00:00:00至 To 2026-12-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-11-03 00:00:00 至 To 2025-12-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后五个月,经合理诉求数据可共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The corresponding authors could be contacted five months after the end of the study, and the data could be shared after obtaining consent |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和数据管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic data capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |